We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Combining Behavioral Treatment With Agonist Maintenance - 1

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified October 2008 by National Institute on Drug Abuse (NIDA).
Recruitment status was:  Active, not recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT00000311
First Posted: September 21, 1999
Last Update Posted: October 29, 2008
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Yale University
Information provided by:
National Institute on Drug Abuse (NIDA)
  Purpose
The purpose of this study is to evaluate whether the community reinforcement approach (CRA) plus contingency management (CM) is more effective overall than CRA only in reducing illicit opioid and cocaine use during agonist maintenance treatment and at 3 and 6 month follow-up after completion of study protocol, and to compare the efficacy of maintenance on buprenorphine to methadone when maintenance is combined with CRA only or CRA plus CM.

Condition Intervention Phase
Cocaine-Related Disorders Opioid-Related Disorders Substance-Related Disorders Drug: Buprenorphine Phase 3

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: Combining Behavioral Treatment With Agonist Maintenance

Resource links provided by NLM:


Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Depression
  • Withdrawal symptoms
  • Opioid and cocaine use
  • Social and psychological functioning
  • AIDS risk behavior

Estimated Enrollment: 168
Study Start Date: September 1999
Arms Assigned Interventions
Experimental: 1
Therapeutic Contracting (TC)
Drug: Buprenorphine
  1. Experimental Therapeutic Contracting (TC)
  2. Experimental Cognitive Behavioral Coping Skills Therapy (CBT)
Experimental: 2
Cognitive Behavioral Coping Skills Therapy (CBT)
Drug: Buprenorphine
  1. Experimental Therapeutic Contracting (TC)
  2. Experimental Cognitive Behavioral Coping Skills Therapy (CBT)

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria
Please contact site for information.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000311


Locations
United States, Connecticut
APT Residential Services Division
New Haven, Connecticut, United States, 06519
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
Yale University
Investigators
Principal Investigator: Richard Schottenfeld, M.D. Yale University
  More Information

Responsible Party: Richard S. Schottenfeld, MD, Yale University School of Medicine
ClinicalTrials.gov Identifier: NCT00000311     History of Changes
Other Study ID Numbers: NIDA-09413-1
R01-09413-1
First Submitted: September 20, 1999
First Posted: September 21, 1999
Last Update Posted: October 29, 2008
Last Verified: October 2008

Additional relevant MeSH terms:
Disease
Substance-Related Disorders
Opioid-Related Disorders
Cocaine-Related Disorders
Pathologic Processes
Chemically-Induced Disorders
Mental Disorders
Buprenorphine
Analgesics, Opioid
Narcotics
Central Nervous System Depressants
Physiological Effects of Drugs
Analgesics
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists